Triglyceride (TG) is known to be associated with inflammatory disease including atherosclerosis. In a variety of atherosclerosis models, T lymphocytes are localized in the earliest lesions of atherosclerosis. T cell associated cytokines such as TNF-α and IFN-γ have pre-dominant inflammatory effects in chronic vascular diseases. In our previous study, we found that the expression of TNF-α and its receptor, TNF-αR was increased when Jurkat T lymphocyte cell lines were exposed to TGs. Therefore, experiments were conducted to determine which cell signaling pathway are involved in the increase of TNF-α and TNF-αR expression by TGs. To identify signal transduction pathways involved in TG-induced upregulation of TNF-α, we treated TG-exposed Jurkat T cells with specific inhibitors for MEK1, PI3K, NF-κB and PKC. We found that inhibition of the MEK1 pathway blocked TG-induced upregulation of TNF-α. However, the expression level of TNF-αR did not change with any signal transduction inhibitor. Based on this observation, we suggest that increase of exogenous TG induces increase of TNF-α expression through MEK1 pathway in Jurkat T cells. In addition, it was confirmed that the increase of TNF-α and TNF-αR expression by TGs occurs via different pathways.
INTRODUCTION
Tumor necrosis factor-α (TNF-α) is one of the typical inflammatory cytokines secreted by inflammatory cells including T cells. It not only stimulates inflammation reaction around the site of inflammation lesion, but also accumulates immune cells that are involved in other inflammatory responses, such as macrophages in the inflammation lesions (Burger and Dayer, 2002; Firestein and Zvaifler, 2002) .
TNF-α is known as a cytokine that bind to TNF-α receptor (TNF-αR) present in most nucleated cells. When TNF-α binds to the TNF-αR, it transmits a signal to the inside of the cell and causes various reactions such as inflammation or apoptosis. The intracellular signaling pathway to receptor binding is a very complex phenomenon, accompanied by phosphorylation or ubiquitination of each target signaling substances (Juge-Aubry et al., 2005; Lira et al., 2009 ). In the inflammatory response, the signaling molecule that plays a key role in the intracellular signaling caused by the interaction between TNF-α and TNF-αR is nuclear factor κB
(NF-κB). When stimulation signal by TNF-α is delivered
Original Article into the cell, inhibitor of κB α (IκBα) is phosphorylated by phosphorylated inhibitor of κB kinase (IKK). IκBα usually binds to NF-κB and inhibits the activation of NF-κB signaling pathway. The phosphorylated IκBα is released from NK-κB in the cytoplasm, and NF-κB migrates from the cytoplasm to the nucleus. Thereafter, NF-κB acts as a transcription factor, producing a variety of inflammatory cytokines and accelerating the inflammatory response (Costa Rosa, 2004; Kanayama et al., 2004; Mund et al., 2007) .
In vascular endothelial inflammatory diseases including atherosclerosis, a chronic inflammatory arterial disease, various cytokine are known to be involved, one of which is TNF-α. Studies have shown that the expression levels of TNF-α are increased in a variety of immune cells found in early lesions of atherosclerosis. And that increased expression of TNF-α directly and indirectly exacerbates inflammatory lesions (Libby et al., 2002; Robertson and Hansson, 2006) . Therefore, increased expression of TNF-α in immune cells involved in chronic inflammatory vascular disease is a very important pathogenic factor.
Among the various factors that cause damage to the blood vessels by the chronic inflammatory response, triglycerides (TGs) have been regarded as one of the causing factor (Gotto, 1998; Aronis et al., 2009) . Several studies have reported that elevated concentrations of TGs in the blood cause inflammatory damage to vascular endothelial cells and promotes the development of vascular inflammatory diseases such as atherosclerosis (Sofer et al., 1992; Kastelein et al., 2008) .
The Framingham Heart Study (FHS), a large observational study of coronary artery disease (CAD), demonstrates that patients with hyperlipidemia with triglyceride (TG) levels above 250 mg/dL had a two-fold increased risk of CAD (Castelli, 1992; Malloy and Kane, 2001 ). However, a detailed mechanism of how TGs affect inflammatory lesions of the blood vessels is still being studied, and there are still some unknowns.
In pathological conditions of atherosclerosis, immune cells such as T lymphocytes and macrophages are involved in the increase of inflammation caused by hyperlipidemia, and these cells are observed in the inflammatory lesions (Libby et al., 2002) . T lymphocytes secrete a variety of cytokines, of which TNF-α and interferon-γ (IFN-γ) are known to increase inflammatory effects in the human immune system. These cytokines stimulates other immune cells, such as macrophages and monocytes, to increase the secretion of inflammatory cytokines, thus accelerating the inflammatory response (Burger and Dayer, 2002) . Therefore, the secretion of inflammatory cytokines from T lymphocytes during the development of inflammatory lesions in the blood vessels is an important mediator.
In this study, we conducted an experiment to determine the relationship between TNF-α expression and triglyceride, which are closely related to the inflammatory response. Then, it was confirmed that the expression of TNF-α by TG was 
MATERIALS AND METHODS

Materials
Cell culture
The Jurkat acute T lymphocyte leukemia cell line (ATCC, Manassas, VA, USA) was grown in RPMI 1640 media supplemented with 10% fetal bovine serum (FBS), 1% MEM non-essential amino acid solution, 1 mM HEPES, 100 μM sodium pyruvate and 1% penicillin-streptomycin and maintained at 37℃ in a humidified atmosphere with 5% CO 2 .
Jurkat cells were seeded in 6-well plates at a density of 2.5 × 10 5 cells/well for 24 h. Thereafter, Jurkat cells were incubated with TG and/or chemical inhibitors for 48 h.
RNA extraction and semi-quantitative reverse transcriptase PCR (RT-PCR)
Total RNA was isolated from Jurkat T lymphocytes using was used as an internal control (Son et al., 2013) . PCR products were electrophoresed on 2% (w/v) agarose gels containing 0.5 μg/mL ethidium bromide and the product size determined by comparison to 100 bp DNA ladder marker (Intron, Gyeonggi, Korea). Gel images were taken using Gel Doc TM XR+ system (Bio-Rad, Hercules, CA, USA). The PCR product band intensity was measured and normalized against GAPDH using Image Lab TM software (version 4.1, Bio-Rad).
Statistical analysis
P-values were calculated using either the Student's t-test.
Values are shown as mean and standard error of the mean (SEM). Each experiment was conducted three times and the data pooled for analysis.
RESULTS
The triglyceride increases TNF-α expression in Jurkat T lymphocytes T lymphocytes secrete inflammatory cytokines such as TNF-α and IFN-γ in vascular inflammatory lesions and are .0 mg/mL) for 24 h. cDNA was prepared from extracted total RNA and subjected to PCR to amplify inflammation-associated cytokines (TNF-α, IFN-γ, and TGF-β). The PCR products were analyzed on a 2% agarose gel. GAPDH was used as internal control. Data were collected from three independent experiments.
known to contribute to the development of early lesions (Libby, 2012) . Therefore, in order to examine whether RT-PCR analysis. We found that TNF-αR expression began to increase by 6 h after TG treatment and continued to increase for 24 h ( Fig. 3A and 3B ). We next determined the concentration at which TG could up-regulate TNF-αR expression. Jurkat T cells were treated with TG (0, 0.05, 0.1, 0.2, 0.5, 1.0 mg/mL) for 48 h and TNF-αR expression assessed by RT-PCR. We found that 0.2 mg/mL of TG was sufficient to induce TNF-αR expression by 48 h (Fig. 3A and 3C ).
These results indicate that gene expression of TNF-αR in
Jurkat T cells is up-regulated in a time-and dose-dependent manner by TG treatment.
Fig. 2. TG increased expression level of TNF-α in Jurkat T lymphocytes. (A)
Jurkat T lymphocytes were treated with TG (0.5 mg/mL) for indicated times (0, 6, 12, 24, and 48 h). (B) Jurkat T lymphocytes were treated with indicated concentration of TG (0, 0.05, 0.1, 0.2, 0.5, and 1.0 mg/mL) for 24 h. cDNA was prepared from extracted total RNA and subjected to PCR to amplify TNF-α. Densitometric analysis was performed. Data are expressed as the mean ± SD and are presented as the expression levels of TNF-α mRNA relative to GAPDH mRNA (The mRNA expression level of TNF-α relative to GAPDH in Jurkat T lymphocytes treated with 0.5 mg/mL TG for 0 h was set as 100). Data are from three independent experiments. GAPDH was used as an internal control. Values are shown as mean and standard error. P-values were determined by Student's t-test (*P<0.05, **P<0.01, and ***P<0.001). (PD98059), PKC (RO31-7549) and PI3-K (LY294002). We found that the MEK1 (PD98059) dramatically blocked TNF-α up-regulation by TG ( Fig. 4A and 4B ). In contrast, It was confirmed that the increase of TNF-αR expression was maintained in any inhibitor treatment ( Fig. 4A and 4C ). These results suggest that TG-induced up-regulation of TNF-α expression requires activation of the MEK1. Furthermore, these results indicate that increased expression of TNF-α and TNF-αR is regulated by different signaling pathways.
Modulation of TNF-α expression in TG treated
DISCUSSION
Studies on the correlation between hypertriglyceridemia and inflammatory lesions such as atherosclerosis are continuing, and TGs are known to be an independent factor that exacerbates the inflammation of intravascular lesions.
Furthermore, a variety of immune cells are involved in the development of these inflammatory lesion sites, and it is known that macrophages and T lymphocytes are involved directly or indirectly. In the early development of the inflammatory response, the inflammatory mediators secreted by these cells activate several other immune cells, including themselves, and this process further exacerbates the inflam-
Fig. 3. TG increased expression level of TNF-αR in Jurkat T lymphocytes. (A)
Jurkat T lymphocytes were treated with indicates concentration of TG (0, 0.05, 0.1, 0.2, 0.5, and 1.0 mg/mL) for indicates times (0, 6, 12, 24, 48 h). cDNA was prepared from extracted total RNA and subjected to PCR to amplify TNF-αR. The PCR products were analyzed on a 2% agarose gel. GAPDH was used as internal control. Data were collected from three independent experiments. (B) and (C) Densitometric analysis was performed. Data are expressed as the mean ± SD and are presented as the expression levels of TNF-αR mRNA relative to GAPDH mRNA (The mRNA expression level of TNF-αR relative to GAPDH in Jurkat T lymphocytes treated with 0.5 mg/mL TG for 0 h was set as 100). Data are from three independent experiments. GAPDH was used as an internal control. Values are shown as mean and standard error. P-values were determined by Student's t-test (*P<0.05, and **P <0.01). (Ross, 1999; Costa Rosa, 2004; Libby, 2012) . TNF-αR is also closely related to the activation of inflammatory lesions. When the receptor binds to TNF-α, the TNF receptor-associated factor (TRAF) protein is activated and consequently the NF-κB migrates to the nucleus, resulting in the expression of various inflammatory mediators such as IL-1β and TNF-α (Coppack, 2001; Lira et al., 2009 ). μM of RO31-7549 (PKC inhibitor) and 20 μM of LY294002 (PI3K inhibitor) during TG treatment (0.5 mg/mL) for 48 h and RT-PCR analysis was performed. GAPDH was used as the internal control for calculating target genes' relative expressions. The PCR products were analyzed on 2% agarose gel and densitometry analysis was performed. (B) and (C) The mRNA expression level of TNF-α and TNF-αR relative to GAPDH in THP-1 macrophages treated without TG was set as a 100. Data are expressed as the mean ± SD and are presented as the mRNA expression levels of TNF-α and TNF-αR relative to GAPDH mRNA. Data were collected from three independent experiments. Values are shown as mean and standard error. P-values were determined by the Student's t-test (*P<0.05).
cription level. Therefore, we will further investigate whether the inflammatory response by TGs affects the secretion of cytokines such as TNF-α and the phosphorylation of inflammation associated signaling molecules.
In this study, experiments were conducted with specific chemical inhibitors to determine which cell signaling molecules are involved in the expression of TNF-α and TNF-αR.
It was confirmed that the increase of TNF-α expression by triglyceride was inhibited by the MEK1 inhibitor. Several reports have shown that the expression of TNF-α is regulated by mitogen activated protein kinase (MAPK) group of signaling molecules (Boulton et al., 1991; Kyriakis et al., 1994) .
The MAPK signaling molecules are known to be involved in the inflammatory process. In general, MAPK pathways are divided into three groups: extracellular signal-regulated kinase (ERK) family, Jun N-terminal kinase (JNK)/stressactivated protein kinase family, and p38 family (Weinstein et al., 1992; Lee et al., 1994; Dziarski et al., 1996) . According with the inflammatory response is also suppressed (Ajizian et al., 1999) . As shown in this study, increased expression of TNF-α by TG is via MEK1. Thus, MEK1 is likely to be an important signaling molecule in the development of inflammatory lesions caused by TGs. Furthermore, the increased expression of TNF-α via MEK1 is also likely to be associated with activation of iNOS protein and NO production.
Inhibition of MEK1 signaling can be used to identify candidates for reducing inflammatory responses caused by TGs.
Apart from this result, the increase in the expression level of TNF-αR was not changed by other specific chemical inhibitors including MEK1. As we have seen, TNF-αR is also an important pathogenic factor in inflammatory diseases, so we need to continue research to find out the mechanism of increased expression of TNF-αR. Although TNF-α and TNF-αR expression by TGs could not be elucidated, it is expected that the increase of TNF-α due to TG in Jurkat T lymphocytes via MEK1 will provide important information for the study of inflammatory lesions caused by hypertriglyceridemia.
